Novo Nordisk A/S

Eli Lilly and Company

Nestle S.A.

Diabetes and obesity drugs based on semaglutide and tirzepatide - Ozempic, Wegowy, Zepbound and other hits from Danish Novo Nordisk and U.S.-based Eli lilly - are not only affecting the pharmaceutical market, but also other industries, including food production, restaurants and even clothing sales. In June, The Wall Street Journal <a href="https://www.wsj.com/business/retail/ozempic-clothing-sizes-weight-loss-80f9f83d">reported</a> on the sudden demand for clothes in small sizes, one of the reasons for which was the widespread availability of new weight-loss drugs;

Business in the age of Ozempic: who will benefit from the growing popularity of weight loss drugs


H & M Hennes & Mauritz AB

PDD Holdings Inc.

Industria de Diseno Textil, S.A.

In June, the French Senate voted in favor of <a href="https://www.thefashionlaw.com/france-focuses-on-shein-temu-in-revised-anti-fast-fashion-legislation/">a bill</a> to restrict advertising and impose environmental fees on ultra-fast fashion companies. The main targets are Chinese giants Temu and Shein. What does this mean for the ultra-fast fashion market, investors, and what does it have to do with zoomers?

#: 2

Business in the age of Ozempic: who will benefit from the growing popularity of weight loss drugs

Exceeding the speed limit: How France is trying to stop the Shein and Temu offensive